Evidence map›Paper›PMID 32219067›Full record

ArticleFrontiers in oncology2020

Risk Stratification Using Multivariable Fractional Polynomials in Diffuse Large B-Cell Lymphoma.

Jin Roh, Jiwon Jung, Yourim Lee, So-Woon Kim, Hyo-Kyung Pak, A-Neum Lee, Junho Lee, Jaehyeong Cho, Hyungwoo Cho, Dok Hyun Yoon and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jin RohDepartment of Pathology, Ajou University School of Medicine, Suwon, South Korea.
Jiwon JungDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Yourim LeeDepartment of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.
So-Woon KimDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Hyo-Kyung PakDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
A-Neum LeeAsan Medical Center, Asan Institute for Life Science, University of Ulsan College of Medicine, Seoul, South Korea.
Junho LeeDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Jaehyeong ChoDepartment of Biomedical Science, Ajou University Graduate School of Medicine, Suwon, South Korea.
Hyungwoo ChoDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Dok Hyun YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Rae Woong ParkDepartment of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.
Jooryung HuhDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Heung-Bum OhDepartment of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Chan-Sik ParkDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The risk stratification of diffuse large B-cell lymphoma (DLBCL) is crucial. The International Prognostic Index, the most commonly used and the traditional risk stratification system, is composed of fixed and artificially dichotomized attributes. We aimed to develop a novel prognostic model that allows the incorporation of up-to-date attributes comprehensively without information loss. We analyzed 204 patients with primary DLBCL who were uniformly treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) from 2007 to 2012 at Asan Medical Center. Using the multivariable fractional polynomial (MFP) method and bootstrap resampling, we selected the variables of significance and the best fitted functional form in fractional polynomials. Age, serum β2-microglobulin, serum lactate dehydrogenase, and BCL2 expression were selected as significant variables in predicting overall survival (OS), while age was excluded in predicting 2-years event-free survival. The prognostic score calculated by the MFP model effectively classifies patients into four risk groups with 5-years OS of 89.91% (low risk), 81.21% (low-intermediate risk), 66.40% (high-intermediate risk), and 37.89% (high risk). We suggest a new prognostic model that is simple and flexible. By using the MFP method, we can incorporate various clinicopathologic factors into a risk stratification system without arbitrary dichotomization.

Indexed as

diffuse large B-cell lymphomamultivariable fractional polynomialprognosisprognostic modelrisk stratification

Identifiers

PMID32219067
PMCPMC7078241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.